Skip to main content
. 2023 Apr 13;18(6):727–738. doi: 10.2215/CJN.0000000000000135

Table 1.

Demographic and clinical characteristics at diagnosis and clinical outcomes during follow-up (full-analysis population)

Category Overall Adult Pediatric
Age at diagnosis, No. (%) 2439 (100) 2299 (100) 140 (100)
 Mean, yrs (SD) 41 (15) 42 (14) 13 (5)
 Median, yrs (Q1, Q3) 40 (29, 51) 41 (31, 52) 14 (10, 17)
Sex, No. (%) 2439 (100) 2299 (100) 140 (100)
 Female 716 (29) 674 (29) 42 (30)
 Male 1723 (71) 1625 (71) 98 (70)
Ethnicity, No. (%) 2439 (100) 2299 (100) 140 (100)
 Asian 228 (9) 221 (10) 7 (5)
 Black 32 (1) 32 (1) 0 (0)
 Mixed 14 (1) 12 (1) 2 (1)
 Others 36 (1) 36 (2) 0 (0)
 White 1885 (77) 1768 (77) 117 (84)
 Not stated/missing 244 (10) 230 (10) 14 (10)
BMI at diagnosis, No. (%) 328 (13) 313 (14) 15 (11)
 Mean, (SD) 28 (8.5) 29 (8.3) 20 (7.9)
 Median, (Q1, Q3) 28 (24.1, 31.5) 28 (24.2, 31.6) 21 (16.2, 24.6)
Systolic BP at diagnosis, No. (%) 299 (12) 287 (12) 12 (9)
 Mean, (SD) 138 (24) 139 (24) 118 (16)
 Median, (Q1, Q3) 137 (124, 152) 138 (125, 153) 113 (108, 127)
UPCR at diagnosis, No. (%) 545 (22) 526 (23) 19 (14)
 Mean, g/ga (SD) 2.42 (3.57) 2.41 (2.72) 2.75 (2.78)
 Median, g/g (Q1, Q3) 1.51 (0.64, 3.13) 1.51 (0.66, 3.09) 2.10 (0.42, 4.04)
 Nephrotic range proteinuria (>2.64 g/g) 169 (7) 161 (7) 8 (6)
eGFR at diagnosis, No. (%) 896 (37) 880 (38) 16 (11)
 Mean, ml/min per 1.73 m2 (SD) 55 (29) 55 (29) 78 (33)
 Median, ml/min per 1.73 m2 (Q1, Q3) 48 (32, 75) 48 (32, 75) 76 (53, 108)
CKD stage at diagnosis, No. (%) 896 (37) 880 (38) 16 (11)
 Stage 1 141 (16) 136 (15) 5 (31)
 Stage 2 197 (22) 191 (22) 6 (38)
 Stage 3 366 (41) 361 (41) 5 (31)
 Stage 4 178 (20) 178 (20) 0 (0)
 Stage 5 14 (2) 14 (2) 0 (0)
Length of follow-up, No. (%) 2439 (100) 2299 (100) 140 (100)
 Mean, yrs (SD) 8.0 (7.3) 7.7 (6.7) 13.4 (12.4)
 Median, yrs (Q1, Q3) 5.9 (3.0, 10.5) 5.8 (2.9, 10.1) 8.2 (5.3, 17.0)
Kidney failure or death event, No. (%) 2439 (100) 2299 (100) 140 (100)
 Yes 1210 (50) 1156 (50) 54 (39)
 No 1229 (50) 1143 (50) 86 (61)
First event, No. (%) 1210 (50) 1156 (50) 54 (39)
 Death 21 (2) 21 (2) 0 (0)
 Dialysis 298 (25) 277 (24) 21 (39)
 Transplant 95 (8) 86 (7) 9 (17)
 eGFR <15 ml/min per 1.73 m2 796 (66) 772 (67) 24 (44)
Time to first event, No. (%) 1210 (50) 1156 (50) 54 (39)
 Mean, yrs (SD) 6.9 (7.1) 6.6 (6.6) 13.6 (12.3)
 Median, yrs (Q1, Q3) 4.5 (1.9, 9.6) 4.3 (1.8, 9.3) 10.2 (6.1, 16.1)
Age at first event, No. (%) 1210 (50) 1156 (50) 54 (39)
 Mean, yrs (SD) 48 (15) 49 (14) 27 (10)
 Median, yrs (Q1, Q3) 48 (37, 58) 49 (38, 59) 24 (21, 32)
Survival rate, estimate (95% CI) 2439 (100) 2299 (100) 140 (100)
 5-year 0.72 (0.70 to 0.74) 0.71 (0.69 to 0.73) 0.91 (0.85 to 0.95)
 10-year 0.54 (0.51 to 0.56) 0.52 (0.50 to 0.55) 0.76 (0.66 to 0.83)
 15-year 0.40 (0.37 to 0.43) 0.38 (0.36 to 0.41) 0.62 (0.52 to 0.72)
 20-year 0.29 (0.27 to 0.32) 0.28 (0.25 to 0.31) 0.52 (0.41 to 0.62)
Quartile survival estimate, yr (95% CI) 2439 (100) 2299 (100) 140 (100)
 75% 4.2 (3.9 to 4.7) 4.0 (3.7 to 4.4) 10.9 (7.3 to 12.4)
 50% 11.4 (10.5 to 12.5) 10.8 (10.0 to 12.0) 21.6 (15.9 to NE)
 25% 24.3 (21.8 to 25.8) 22.9 (19.6 to 25.5) NE (NE to NE)
eGFR slope, total, No. (%) 1863 (76) 1795 (78) 68 (49)
 Mean, ml/min per 1.73 m2/yr (SD) −3.6 (8.2) −3.7 (7.4) −2.2 (19.6)
 Median, ml/min per 1.73 m2/yr (Q1, Q3) −2.4 (−5.7, −0.6) −2.4 (−5.6, −0.6) −3.6 (−8.3, −0.9)

Q, quartile; BMI, body mass index; UPCR, urinary protein-creatinine ratio; CI, confidence interval; NE, not estimable.

a

0.0088 g/g=1 mg/mmol.